The use of second-generation antipsychotics (SGAs) for the treatment of schizophrenia has surged worldwide. Amisulpride, aripiprazole, olanzapine, quetiapine, risperidone, sertindole and ziprasidone have now been commonly prescribed. Their effects on QT interval differ but evidence remains sparse and mostly inconclusive. Since prolongation of heart-rate corrected QT interval has been implicated as an useful surrogate marker to predict drug-related cardiac mortality and pro-arrhythmic potentials, it is timely and necessary to compare the effects of Bazett’s corrected QT interval (QTBc) prolongation for the commonly prescribed SGAs. A meta-analysis was conducted according to suggestions by the Quality of Reporting of Meta-analysis group with literature identified using various databases and augmented with hand-searching to assess the magnitude and risk on QTBc prolongation by these seven SGAs for treatments in adult subjects with schizophrenia. Because of incomplete QTBc data reporting, quetiapine could not be assessed by the meta-analytical approach in this study. Aripiprazole was the only SGA associated with both statistically significant lower risk and mean change in QTBc, with sertindole giving a statistically significant worsening effect on mean QTBc. Other analyses did not demonstrate any statistically significant pooled effects for the studied SGAs, neither on the magnitude over mean or mean change, nor the risk on QTBc prolongation.
AgelinkMWMajewskiTWurthmannCLukasKUllrichHLinkaT (2001) Effects of newer atypical antipsychotics on autonomic neurocardiac function: a comparison between amisulpride, olanzapine, sertindole, and clozapine. J Clin Psychopharmacol21: 8–13.
2.
AlgraATijssenJGRoelandtJRPoolJLubsenJ (1991) QTc prolongation measured by standard 12-lead electrocardiography is an independent risk factor for sudden death due to cardiac arrest. Circulation83: 1888–1894.
3.
AlgraATijssenJGRoelandtJRPoolJLubsenJ (1993) QT interval variables from 24 hour electrocardiography and the two year risk of sudden death. Br Heart J70: 43–48.
4.
Al-KhatibSMLaPointeNMKramerJMCaliffRM (2003) What clinicians should know about the QT interval. JAMA289: 2120–2128.
AmesDCammJCookPFalkaiPGuryCHurleyR (2002) Minimizing the risks associated with significant QTc prolongation in people with schizophrenia: a consensus statement by the Cardiac Safety in Schizophrenia Group. Australas Psychiatry 10115–124.
7.
ArvanitisLAMillerBGthe Seroquel Trial 13 Study Group (1997) Multiple fixed doses of ‘Seroquel’ (Quetiapine) in patients with acute exacerbation of schizophrenia: a comparison with haloperidol and placebo. Biol Psychiatry42: 233–246.
8.
AuquierPLaconCRouillonFLaderMHolmesC (2006) Mortality in schizophrenia. Pharmacoepidemiol Drug Safety15: 873–879.
9.
AzorinJStrubNLoftH (2006) A double-blind, controlled study of sertindole versus risperidone in the treatment of moderate-to-severe schizophrenia. Int Clin Psychopharmacol21: 49–56.
10.
BagnallAMKleijnenJLeitnerMLewisR (2000) Ziprasidone for schizophrenia and severe mental illness. Cochrane Database of Systematic Reviews. (Issue 4) Art. No.: CD001945. DOI: 10.1002/14651858.CD001945.
11.
BeasleyCMJrSangerTSatterleeWTollefsonGTranPHamiltonSthe Olanzapine HGAP Study Group (1996a) Olanzapine versus placebo: results of a double-blind, fixed-dose olanzapine trial. Psychopharmacology (Berl)124: 159–167.
12.
BeasleyCMJrTollefsonGTranPSatterleeWSangerTHamiltonSthe Olanzapine HGAD Study Group (1996b) Olanzapine versus placebo and haloperidol: acute phase results of the North American double-blind olanzapine trial. Neuropsychopharmacology14: 111–123.
13.
BhattacharjeeJEl-SayehHGG (2008) Aripiprazole versus typical antipsychotic drugs for schizophrenia. Cochrane Database of Systematic Reviews (Issue 3) Art. No.: CD006617. DOI: 10.1002/14651858.CD006617.pub3.
14.
BorisonRLArvanitisLAMillerBG (1996) ICI 204,636, an atypical antipsychotic: efficacy and safety in a multicenter, placebo-controlled trial in patients with schizophrenia. J Clin Psychopharmacol16: 158–169.
15.
BrownS (1997) Excess mortality of schizophrenia. A meta-analysis. Br J Psychiatry171: 502–508.
16.
Canadian Psychiatric Association (2005) Clinical practice guidelines: treatment of schizophrenia. Can J Psychiatry50Supp. 11S–56S.
17.
ChanHLinWLinSHwangTSuTTChiangS (2007) Efficacy and safety of aripiprazole in the acute treatment of schizophrenia in Chinese patients with risperidone as an active control: a randomized trial. J Clin Psychiatry68: 29–36.
18.
ClausABollenJDe CuyperHEnemanMMalfroidMPeuskensJ (1992) Risperidone versus haloperidol in the treatment of chronic schizophrenic patients: a multicentre double-blind comparative study. Acta Psychiatr Scand85: 295–305.
19.
Cochrane Collaboration (2009) Review Manager (RevMan) Version 5.0.20 [Computer program]Copenhagen: The Nordic Cochrane Centre.Available at http://www.cc-ims.net/revman (accessed May 12, 2009).
20.
ConleyRRMahmoudR (2001) A randomized double-blind study of risperidone and olanzapine in the treatment of schizophrenia and schizoaffective disorder. Am J Psychiatry158: 765–774.
21.
CurranMPPerryCM (2001) Amisulpride. A review of its use in the management of schizophrenia. Drug61: 2123–2150.
22.
CzekallaJKollack-WalkerSBeasleyCMJr (2001a) Cardiac safety parameters of olanzapine: comparison with other atypical and typical antipsychotics. J Clin Psychiatry62Suppl. 235–40.
23.
CzekallaJBeaselyCMJrDellvaMABergPHGrundyS (2001b) Analysis of the QTc interval during olanzapine treatment of patients with schizophrenia and related psychosis. J Clin Psychiatry62: 191–198.
24.
DugganLFentonMRathboneJDardennesREl-DosokyAIndranS (2005) Olanzapine for schizophrenia. Cochrane Database of Systematic Reviews (Issue 2) Art. No.: CD001359. DOI: 10.1002/14651858.CD001359.pub2.
25.
EggerMSmithDGSchneiderMMinderC (1997) Bias in meta-analysis detected by a simple, graphical test. BMJ315: 629–634.
26.
El-SayehHGGMorgantiC (2006a) Aripiprazole for schizophrenia. Cochrane Database of Systematic Reviews (Issue 2) Art. No.: CD004578. DOI: 10.1002/14651858. CD004578.pub3.
European Medicines Agency (EMEA) Committee for Proprietary Medicinal Products (1997) The Assessment of the Potential for QT Interval Prolongation by Non-cardiovascular Medicinal ProductsAvailable at http://www.fda.gov/OHRMS/DOCKETS/ac/03/briefing/pubs%5Ccpmp.pdf (accessed May 14, 2009).
30.
European Medicines Agency (EMEA) Committee for Medicinal Products for Human Use (CHMP) (2005a) The Clinical Evaluation of QT/QTc Interval Prolongation and Proarrhythmic Potential for Non-Antiarrhythmic DrugsAvailable at http://www.emea.europa.eu/pdfs/human/ich/000204en.pdf (accessed March 22, 2008).
31.
European Medicines Agency (EMEA) Committee for Proprietary Medicinal Products (CPMP) (2005b) The Non-clinical Evaluation of the Potential for Delayed Ventricular Repolarization (QT Interval Prolongation) by Human Pharmaceuticals. Note for Guidance on the Non-Clinical Evaluation of the Potential for Delayed Ventricular Repolarization (QT Interval Prolongation) by Human PharmaceuticalsAvailable at http://www.emea.europa.eu/pdfs/human/ich/042302en.pdf (accessed March 22, 2008).
32.
FabreLFArvanitisLPultzJJonesVMMalickJBSlotnickVB (1995) ICI 204,636, a novel, atypical antipsychotic: early indication of safety and efficacy in patients with chronic and subchronic schizophrenia. Clin Ther17: 366–378.
FenichelRRMalikMAntzelevitchCSanguinettiMRodenDMPrioriSG (2004) Drug-induced Torsade de Pointes and implications for drug development. J Cardiovasc Electrophysiol15: 475–495.
35.
FleischhackerWWMcQuadeRDMarcusRNArchibaldDSwaninkRCarsonWH (2009) A double-blind, randomized comparative study of aripiprazole and olanzapine in patients with schizophrenia. Biol Psychiatry65: 510–517.
36.
Food and Drug Administration (FDA) (2002) The Clinical Evaluation of QT/QTc Interval Prolongation and Proarrhythmic Potential for Non-antiarrhythmic DrugsPreliminary Concept Paper. Available at http://www.fda.gov/ohrms/dockets/ac/03/briefing/pubs%5Cprelim.pdf (accessed March 22, 2008).
GilbodySBagnallAMDugganLTuunainenA (2000) Risperidone versus other atypical antipsychotic medication for schizophrenia. Cochrane Database of Systematic Reviews (Issue 3) Art. No.: CD002306. DOI: 10.1002/14651858. CD002306.
39.
GlassmanAHBiggerJT (2001) Antipsychotic drugs: prolonged QTc Interval, Torsade de Pointes, and sudden death. Am J Psychiatry158: 1774–1782.
40.
GoffDCSullivanLMMcEvoyJPMeyerJMNasrallahHADaumitGL (2005) A comparison of ten-year cardiac risk estimates in schizophrenia patients from the CATIE study and matched controls. Schizophr Res80: 45–53.
41.
GoodnickPJJerryJParraF (2002) Psychotropic drugs and the ECG: focus on the QTc interval. Expert Opin Pharmacother3: 479–498.
42.
GuptaALawrenceATKrishnanKKavinskyCJTrohmanRG (2007) Current concepts in the mechanisms and management of drug-induced QT prolongation and Torsade de Pointes. Am Heart J153: 891–899.
43.
HaddadPMAndersonIM (2002) Antipsychotic-related QTc prolongation, Torsade de Pointes and sudden death. Drugs62: 1649–1671.
44.
HamannJKisslingWLeuchtSRummel-KlugeC (2003) New generation antipsychotics for first episode schizophrenia. Cochrane Database of Systematic Reviews (Issue 4) Art. No.: CD004410. DOI: 10.1002/14651858. CD004410.
45.
HarriganEPMiceliJJAnzianoRWatskyEReevesKRCutlerNR (2004) A randomized evaluation of the effects of six antipsychotic agents on QTc, in the absence and presence of metabolic inhibition. J Clin Psychopharmacol24: 62–69.
46.
HennessySBilkerWBKnaussJSMargolisDJKimmelSEReynoldsRF (2002) Cardiac arrest and ventricular arrhythmia in patients taking antipsychotic drugs: cohort study using administrative data. BMJ325: 1070–1074.
47.
HigginsJPTThompsonSGDeeksJJAltmanDG (2003) Measuring inconsistency in meta-analysis. BMJ327: 557–560.
48.
HigginsJPTGreenS (eds) (2008) Cochrane Handbook for Systematic Reviews of Interventions. The Cochrane Collaboration. West Sussex: Wiley-Blackwell.
49.
HodgesM (1997) Rate correction of the QT interval. Cardiac Electrophysiol Rev3: 360–363.
50.
HunterRKennedyESongFGadonLIrvingCB (2003) Risperidone versus typical antipsychotic medication for schizophrenia. Cochrane Database of Systematic Reviews (Issue 2) Art. No.: CD000440. DOI: 10.1002/14651858. CD000440.
51.
JadadARMooreRACarrollDJenkinsonCReynoldsDJMGavaghanDJ (1996) Assessing the quality of reports of randomized clinical trials: is blinding necessary?Controlled Clin Trials17: 1–12.
52.
JayaramMBHosalliPStroupTS (2006) Risperidone versus olanzapine for schizophrenia. Cochrane Database of Systematic Reviews (Issue 2) Art. No.: CD005237. DOI: 10.1002/14651858.CD005237.pub2.
53.
KahnRSSchulzSCPalazovVDReyesEBBrecherMSvenssonO (2007) Efficacy and tolerability of once-daily extended release quetiapine fumarate in acute schizophrenia: a randomized, double-blind, placebo-controlled study. J Clin Psychiatry68: 832–842.
54.
KahnRSFleischhackerWWBoterHDavidsonMVergouweYKeetIPM (2008) Effectiveness of antipsychotic drugs in first-episode schizophrenia and schizophreniform disorder: an open randomized clinical trial. Lancet371: 1085–1097.
55.
KaneJMCarsonWHSahaARMcQuadeRDIngenitoGGZimbroffDL (2002) Efficacy and safety of aripiprazole and haloperidol versus placebo in patients with schizophrenia and schizoaffective disorder. J Clin Psychiatry63: 763–771.
56.
KaneJMKhannaSRajadhyakshaSGillerE (2006) Efficacy and tolerability of ziprasidone in patients with treatment-resistant schizophrenia. Int Clin Psychopharmacol21: 21–28.
57.
KomossaKRummel-KlugeCHungerHSchwarzSSchmidtFLewisR (2009) Sertindole versus other atypical antipsychotics for schizophrenia. Cochrane Database of Systematic Reviews (Issue 2) Art. No.: CD006752. DOI: 10.1002/14651858. CD006752.pub2.
58.
KongsamutSKangJChenXLRoehrJRampeD (2002) A comparison of the receptor binding and HERG channel affinities for a series of antipsychotic drugs. Eur J Pharmacol450: 37–41.
59.
LeuchtSArbterDEngelRRKisslingWDavisJM (2009a) How effective are second-generation antipsychotic drugs? A meta-analysis on of placebo-controlled trials. Mol Psychiatry14: 429–447.
60.
LeuchtSCarvesCArbterDEngelRRLiCDavisJM (2009b) Second-generation versus first-generation antipsychotic drugs for schizophrenia: a meta-analysis. Lancet373: 31–41.
61.
LeuchtSKamossaKRummel-KlugeCCarvesCHungerHSchmidF (2009c) A meta-analysis of head-to-head comparions of second-generation antipsychotics in the treatment of schizophrenia. Am J Psychiatry166: 152–163.
62.
LewisRBagnallAMLeitnerM (2005) Sertindole for schizophrenia. Cochrane Database of Systematic Reviews (Issue 3) Art. No.: CD001715. DOI: 10.1002/14651858. CD001715.pub2.
63.
LiebermanJAStroupTSMcEvoyJPSwartzMSRosenheckRAPerkinsDO (2005) Effectives of antipsychotic drugs in patients with chronic schizophrenia. N Engl J Med353: 1209–1223.
64.
LindstromEFardeLEberhardJHaverkampW (2005) QTc interval prolongation and antipsychotic drug treatments: focus on sertindole. Int J Neuropsychopharmacol8: 615–629.
65.
LiperotiRGambassiGLapaneKLChiangCPedoneCMorV (2005) Conventional and atypical antipsychotics and the risk of hospitalization for ventricular arrhythmias or cardiac arrest. Arch Intern Med165: 969–701.
66.
Lundbeck LtdSertindole Monograph. 2006.
67.
McEvoyJPDanielDGCarsonWHJrMcQuadeRDMarcusRN (2007) A randomized, double-blind, placebo-controlled, study of the efficacy and safety of aripiprazole 10, 15 or 20 mg/day for the treatment of patients with acute exacerbations of schizophrenia. J Psychiatr Res41: 895–905.
68.
MinSKRheeCSKimCKangD (1993) Risperidone versus haloperidol in the treatment of chronic schizophrenic patients: a parallel group double-blind comparative trial. Yonsei Med J 34(2): 179–190.
69.
MoherDPhamBJonesACookDJJadadARMoherM (1998) Does quality of reports of randomised trials affect estimates of intervention efficacy reported in meta-analyses?Lancet352: 609–613.
70.
MoherDCookDJEastwoodSOlkinIRenniwDStroupDFfor the QUOROM group (1999a) Improving the quality of reports meta-analyses of randomized controlled trials: the QUOROM statement. Lancet354: 1896–1900.
71.
MoherDPhamBJonesACookDJJadadARMoherM (1999b) Assessing the quality of reports of randomized trials: implications for the conduct of meta-analyses. Health Technol Assess3: 19–24.
72.
MontanezARuskinJNHebertPRLamasGAHennekensCH (2004) Prolonged QTc interval and risks of total and cardiovascular mortality and sudden death in the general population. A review and qualitative overview of the prospective cohort studies. Arch Intern Med164: 943–948.
National Institute of Clinical Excellence (NICE) (2009) Core interventions in the treatment and management of schizophrenia in primary and secondary care (update). National clinical practice guideline number 82Available at http://www.nice.org.uk/nicemedia/pdf/CG82FullGuideline.pdf (accessed July 23, 2009).
76.
PeuskensJon behalf of the Risperidone Study Group (1995) Risperidone in the treatment of patients with chronic schizophrenia: a multi-national, multi-centre, double-blind, parallel-group study versus haloperidol. Br J Psychiatry166: 712–726.
77.
PeuskensJLinkCGG (1997) A comparison of quetiapine and chlorpromazine in the treatment of schizophrenia. Acta Psychiatr Scand96: 265–273.
78.
PeuskensJBechPMollerHBaleRFleurotOReinWthe Amisulpride study group (1999) Amisulpride vs risperidone in the treatment of acute exacerbations of schizophrenia. Psychiatry Res88: 107–117.
79.
Pfizer IncZeldox Monograph. 2002.
80.
PotkinSGSahaARKujawaMJCarsonWHAliMStockE (2003) Aripiprazole, an antipsychotic with a novel mechanism of action, and risperidone vs placebo in patients with schizophrenia and schizoaffective disorder. Arch Gen Psychiatry60: 681–690.
81.
PriceLH (2009) Correspondance. Atypical antipsychotic drugs and the risk of sudden cardiac death. N Engl J Med360: 2137–2137.
82.
PrioriSGSchwartzPJNapolitanoCBloiseRRonchettiEGrilloM (2003) Risk stratification in the long-QT syndrome. N Engl J Med348: 1866–1874.
83.
Psychopharmacological Drugs Advisory Committee (2000) FDA Background on ZeldoxTM (Ziprasidone Hydrochloride capsules) Pfizer, Inc. Cardio ReviewAvailable at http://www.fda.gov/ohrms/dockets/ac/00/backgrd/3619b1b.pdf (accessed March 22, 2008).
84.
RayWAMeredithSThapaPBMeadorKGHallKMurrayKT (2001) Antipsychotics and the risk of sudden cardiac death. Arch Gen Psychiatry58: 1161–1167.
85.
RayWAChungCPMurrayKTHallKSteinCM (2009) Atypical antipsychotic drugs and the risk of sudden cardiac death. N Engl J Med360: 225–235.
86.
ReillyJGAyisSAFerrierINJonesSJThomasSHL (2000) QTc-interval abnormalities and psychotropic drug therapy in psychiatric patients. Lancet355: 1048–1052.
87.
RodenDM (2004) Drug-Induced prolongation of the QT interval. N Engl J Med350: 1013–1022.
88.
Royal College of Psychiatrists (2006) Consensus statement on high-dose antipsychotic medication. Council Report CR 138, 24Available at http://www.rcpsych.ac.uk/files/pdfversion/CR138.pdf (accessed July 23, 2009).
89.
SacchettiEGalluzzoAValsecchiPRomeoFGoriniBWarringtonLon behalf of the INITIATIVE Study Group (2009) Ziprasidone vs clozapine in schizophrenia patients refractory to multiple antipsychotic treatments: the MOZART study. Schizophr Res110: 80–89.
90.
SahaSChantDMcgrathJ (2007) A systematic review of mortality in schizophrenia. Is the differential mortality gap worsening over time?Arch Gen Psychiatry64: 1123–1131.
91.
ShahRR (2002) Drug-induced prolongation of the QT interval: regulatory dilemmas and implications for approval and labeling of a new chemical entity. Fund Clin Pharmacol16: 147–156.
92.
SicouriSAntzelevitchC (2008) Sudden cardiac death secondary to antidepressant and antipsychotic drugs. Expert Opin Drug Saf7: 181–194.
93.
Silveira da Mota NetoJISoaresBSilva de LimaM (2002) Amisulpride for schizophrenia. Cochrane Database of Systematic Reviews (Issue 2) Art. No.: CD001357. DOI: 10.1002/14651858. CD001357.
94.
SmallJGHirschSRArvanitisLAMillerBGLinkCGG (1997) Quetiapine in patients with schizophrenia: a high- and low-dose double-blind comparison with placebo. Arch Gen Psychiatry54: 549–557.
95.
SrisurapanontMManeetonBManeetonN (2004) Quetiapine for schizophrenia. Cochrane Database of Systematic Reviews (Issue 2) Art. No.: CD000967. DOI: 10.1002/14651858. CD000967.pub2.
96.
SterneJACBeckerBJEggerMThe Funnel Plot. Publication Bias in Meta-analysis. Prevention, Assessment and Adjustments2005West Sussex: John Wiley & Sons Ltd, 75–98.
97.
StollbergerCHuberJOFinstererJ (2005) Antipsychotic drugs and QT prolongation. Int Clin Psychopharmacol20: 243–251.
98.
StrausJMBleuminkGSDielemanJPLeiJVDJong GW’tKingmaJH (2004) Antipsychotics and the risk of sudden cardiac death. Arch Intern Med164: 1293–1297.
ThompsonSG (1994) Systematic review: why sources of heterogeneity in meta-analysis should be investigated. BMJ309: 1351–1355.
101.
TitierKCanalMDeridetEAbouelfathAGrombSMolimardM (2004) Determination of myocardium to plasma concentration ratios of five antipsychotic drugs: comparison with their ability to induce arrhythmia and sudden in clinical practice. Toxicol Appl Pharmacol199: 52–60.
102.
TitierKGirodetPOVerdouxHMolimardMBegaudBHaverkampW (2005) Atypical antipsychotics. From potassium channels to Torsade de Pointes and sudden death. Drug Safety28: 35–51.
103.
TranPVHamiltonSHKuntzAJPotvinJHAndersenSWBeasleyCJr (1997) Double-blind comparison of olanzapine versus risperidone in the treatment of schizophrenia and other psychotic disorders. J Clin Psychopharmacol17: 407–418.
104.
TuunainenAWahlbeckKGilbodyS (2000) Newer atypical antipsychotic medication versus clozapine for schizophrenia. Cochrane Database of Systematic Reviews (Issue 2) Art. No.: CD000966. DOI: 10.1002/14651858. CD000966.
105.
Van DrielMLDe SutterADe MaeseneerJChristiaensT (2009) (6 January 2009) Searching for unpublished trials in Cochrane reviews may not be worth the effort. J Clin Epidemiol62: 838–844.
